Novo Nordisk A/S

NYSE NVO

Data sourced from

and

Daily

Download Data

Novo Nordisk A/S Price to Sales Ratio (P/S) on June 03, 2024

Novo Nordisk A/S Price to Sales Ratio (P/S) is NA on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Novo Nordisk A/S 52-week high Price to Sales Ratio (P/S) is 15.18 on September 11, 2023, which is NA below the current Price to Sales Ratio (P/S).
Novo Nordisk A/S 52-week low Price to Sales Ratio (P/S) is 6.92 on September 29, 2023, which is NA below the current Price to Sales Ratio (P/S).
Novo Nordisk A/S average Price to Sales Ratio (P/S) for the last 52 weeks is 12.47.

NYSE: NVO

Novo Nordisk A/S

CEO	Mr. Lars Fruergaard Jorgensen
IPO Date	Jan. 4, 1982
Location	Denmark
Headquarters	Novo Allé 1, Bagsvaerd, Denmark, 2880
Employees	66,015
Sector	Healthcare
Industry	Biotechnology

Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Key trends